Literature DB >> 18274744

Staging the axilla with selective sentinel node biopsy in patients with previous excision of non-palpable and palpable breast cancer.

R Ruano1, M Ramos, J R Garcia-Talavera, E Serrano, A De Arriba, J Gonzalez-Orus, M Iglesias, M C Macias.   

Abstract

PURPOSE: To present our experience in the therapeutic approach of the sentinel node biopsy (SNB) in patients with previous excision of the breast cancer, divided in non-palpable and palpable lesions, in comparison with time treatment and stagement of breast cancer.
METHODS: In the period 2001-2006, 138 patients with prior diagnostic excisional biopsy (96 non-palpable and 42 palpable breast cancer) and 328 without previous surgery (32 non-palpable; 296 palpable cancer) were treated. The combined technique ((99m)Tc-colloidal rhenium and isosulfan blue dye) was the approach for sentinel lymph node (SLN) detection. Axillary lymph node dissection (ALND) was completed only when the SLN was positive for metastasis or not located.
RESULTS: Detection rate, if there was prior surgery, was 95% for non-palpable and 98% for palpable cancer, and 99% for one-time treatment group. Metastasis rate in the SLN was 15% in non-palpable cancer (14/91), significantly smaller than in palpable breast cancer (39% if prior surgery and 37% in one-time surgery). According to tumoral size, ALND metastasis rate was similar for T1 and T2 tumors (43-44%). In the follow-up of the groups with prior diagnostic biopsy or surgery of the breast cancer we have not found any false negative in the axilla.
CONCLUSION: The detection of the SLN is also feasible in patients with previous surgery of breast cancer. Because SLN metastasis rates are significantly smaller in non-palpable lesions, the effort in screening programs for early detection of breast cancer and also in improving histopathological confirmation of malignancy with ultrasound or stereotactic guided core biopsies must continue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18274744     DOI: 10.1007/s00259-008-0730-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  26 in total

1.  Sentinel lymph node biopsy for breast cancer: combined dye-isotope technique.

Authors:  C E Cox; C Salud; G F Whitehead; D S Reintgen
Journal:  Breast Cancer       Date:  2000       Impact factor: 4.239

2.  An original approach in the diagnosis of early breast cancer: use of the same radiopharmaceutical for both non-palpable lesions and sentinel node localisation.

Authors:  P J Tanis; O E Nieweg; R A Valdés Olmos; C A Hoefnagel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03       Impact factor: 9.236

3.  Axillary sentinel lymph nodes in breast cancer: a single lymphatic pathway drains the entire mammary gland.

Authors:  G Zavagno; D Rubello; Z Franchini; F Meggiolaro; A Ballarin; D Casara; V Denetto; A Marchet; L Rampin; C Polico; D Nitti; G Mariani
Journal:  Eur J Surg Oncol       Date:  2005-04-26       Impact factor: 4.424

Review 4.  Sentinel node biopsy for breast cancer: technical aspects and controversies.

Authors:  Kazuyoshi Motomura; Chiyomi Egawa; Yoshifumi Komoike; Tatsuki Kataoka; Sachiko Nagumo; Hiroki Koyama; Hideo Inaji
Journal:  Breast Cancer       Date:  2007       Impact factor: 4.239

5.  Sentinel node biopsy in non-palpable breast cancer and in patients with a previous diagnostic excision.

Authors:  F Celebioglu; J Frisell; R Danielsson; L Bergkvist
Journal:  Eur J Surg Oncol       Date:  2006-12-18       Impact factor: 4.424

6.  Surgical management of early stage invasive breast cancer: a practice guideline.

Authors:  David McCready; Claire Holloway; Wendy Shelley; Nancy Down; Paula Robinson; Susan Sinclair; Douglas Mirsky
Journal:  Can J Surg       Date:  2005-06       Impact factor: 2.089

7.  Radioguided localisation of non-palpable breast lesions and simultaneous sentinel lymph node mapping.

Authors:  Alfredo Barros; Maria Aparecida Cardoso; Peng Yong Sheng; Paulo Aguirre Costa; Christina Pelizon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10-10       Impact factor: 9.236

8.  Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer.

Authors:  Z Radovanovic; A Golubovic; A Plzak; B Stojiljkovic; D Radovanovic
Journal:  Eur J Surg Oncol       Date:  2004-11       Impact factor: 4.424

9.  Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy.

Authors:  S M Feldman; D N Krag; R K McNally; B B Moor; D L Weaver; P Klein
Journal:  J Am Coll Surg       Date:  1999-03       Impact factor: 6.113

10.  Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer.

Authors:  Rakesh Kumar; Suman Jana; Sherif I Heiba; Mahmoud Dakhel; Deborah Axelrod; Beth Siegel; Stephanie Bernik; Christopher Mills; Marc Wallack; Hussein M Abdel-Dayem
Journal:  J Nucl Med       Date:  2003-01       Impact factor: 10.057

View more
  3 in total

Review 1.  Current status of sentinel lymph-node biopsy in patients with breast cancer.

Authors:  Gang Cheng; Stephanie Kurita; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-11       Impact factor: 9.236

2.  Value of sentinel lymph node biopsy in breast cancer patients with previous excisional biopsy.

Authors:  Gokhan Coskun; Lutfi Dogan; Niyazi Karaman; Cihangir Ozaslan; Can Atalay
Journal:  J Breast Cancer       Date:  2012-03-28       Impact factor: 3.588

Review 3.  The sentinel node in breast cancer.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2008-10-04       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.